All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 174 of 206 pages ‹ First < 172 173 174 175 176 > Last ›
HSL6687
Schering-Plough claims patients should not “fear rebound” with Nitro-Dur and Ciba-Geigy claims Transderm-Nitro has “benefits beyond angina prevention”
MaLAM Australian News 1996 Jul-Aug;4:(7-8):1-2
HSL6688
Conlan MF.
In-your-face pharmacy: will the boom in Rx ads aimed at consumers continue?
Drug Topics 1996 Jul;140:92-94, 97-98
HSL6680
Direct-to-consumer advertising of prescription pharmaceuticals: a Merck Frosst position paper on how to use comprehensive patient information to deliver improved, cost-effective health outcomes
: Merck Frosst 1996 Jun 17
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL595
Shaughnessy AF, Slawson DC.
Pharmaceutical representatives.
BMJ 1996 Jun 15;312:(7045):1494
http://www.bmj.com/cgi/content/full/312/7045/1494
HSL9146
Bloor K, Freemantle N.
Lessons from international experience in controlling pharmaceutical expenditure II: Influencing doctors
British Medical Journal 1996 Jun 15;312:1525-1527
http://www.bmj.com/cgi/content/full/312/7045/1525
HSL6679
Green Shield Canada
Re: direct-to-consumer prescription drug advertising (DTCA)
: Green Shield Canada 1996 Jun 10
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL601
Robb N.
Sale of prescribing data by pharmacists causes growing concern among physicians.
CMAJ 1996 Jun 1;154:(11):1747-9
HSL1867
Kelly MH, Murray TS.
Motivation of general practitioners attending postgraduate education.
Br J Gen Pract 1996 Jun;46:(407):353-6
HSL6665
Health Action International
Drug policy at the 49th World Health Assembly
Amsterdam: Health Action International 1996 Jun
www.haiweb.org
HSL6672
Drug advertising: is this good medicine?
Consumer Reports 1996 Jun;62-63
HSL6673
Canadian Drug Manufacturers Association
Direct-to-consumer advertising of prescription medications
Toronto, Ontario: Canadian Drug Manufacturers Association 1996 Jun
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6674
Canadian Public Health Association
Submission to consensus conference on direct-to-consumer advertising of prescription drugs
: Canadian Public Health Association 1996 Jun
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6675
Canadian Society of Hospital Pharmacists
Response to questions to be addressed by the Drugs Directorate consultation workshop on direct-to-consumer advertising (DTCA) of prescription drugs
: Canadian Society of Hospital Pharmacists 1996 Jun
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6676
Critser G.
Oh, how happy we will be: pills, paradise, and the profits of the drug companies
Harper’s 1996 Jun39-48
HSL6677
Lexchin J, Vitry A.
Re: the promotion of flagyl (metronidazole)
1996 Jun;
HSL6678
Knowledge is the best medicine: Ontario and PEI partner with PMAC to educate consumers on proper use of medicine
PMAC News 1996 Jun-Jul;5-6
HSL8344
Amar D.
Radical reform hits France's health care system
Pharmaceutical Executive 1996 Jun;16:34-36
HSL8345
Drug advertising: is this good medicine?
Consum Rep 1996 Jun;61:(6):62-3
HSL6671
Consultation workshop: background paper. Direct-to-consumer advertising of prescription drugs
: Drugs Programme 1996 May 28
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL585
Vitry A, Mansfield P.
Promotion of Coversyl by Servier.
Lancet 1996 May 18;347:(9012):1411
HSL6670
Canadian Pharmaceutical Association
Re: Drugs directorate consultation workshop on direct-to-consumer prescription drug advertising
: Canadian Pharmaceutical Association 1996 May 16
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6669
Pharmaceutical Advertising Advisory Board
Position paper on direct-to-consumer (DTC) prescription drug promotional materials
: Pharmaceutical Advertising Advisory Board 1996 May 15
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6667
The Migraine Foundation
Position paper on direct to consumer advertising of prescription medications
: The Migraine Foundation 1996 May 10
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6668
Morrice D
1996 May 10
http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL9158
Mahaney LM.
Implications of multitier pricing.
Am J Health Syst Pharm 1996 May 1;53:(9):1002,
HSL6661
Consultation workshop to examine direct-to-consumer advertising
PMAC News 1996 May;12-14
HSL6662
Towards a better informed consumer of prescription medicines
Ottawa: Pharmaceutical Manufacturers Association of Canada 1996 May
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6663
Position paper on direct to consumer prescription drug advertising
: Canadian Medical Association 1996 May
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6664
Consumers’ Association of Canada
Protecting the consumer interest in direct-to-consumer advertising of prescription drugs
: Consumers’ Association of Canada 1996 May
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6666
Lexchin J, Vitry A.
Re: the promotion of Multiload Cu 375
1996 May;
HSL8920
Wechsler J.
Tug-of-war with FDA
Pharmaceutical Executive 1996 May;16:18, 20, 22
HSL8921
Vivian JC.
False claims of pharmacist support enjoined in OTC H2 advertising war
Michigan Pharmacist 1996 May;34:33-34
HSL9142
Wechsler J.
Washington report: SUPAC vs MedGuide: FDA ups and downs
Pharmaceutical Technology Europe 1996 May;8:16, 18, 20
HSL620
Huston P, Moher D.
Redundancy, disaggregation, and the integrity of medical research.
Lancet 1996 Apr 13;347:(9007):1024-6
HSL15301
Armstrong D, Reyburn H, Jones R.
A study of general practitioners' reasons for changing their prescribing behaviour.
BMJ 1996 Apr 13;312:(7036):949-52
http://www.bmj.com/cgi/content/full/312/7036/949?view=long&pmid=8616310
HSL639
Anderson GM, Lexchin J.
Strategies for improving prescribing practice.
CMAJ 1996 Apr 1;154:(7):1013-7
http://www.cma.ca/cmaj/vol-154/1013e.htm
HSL9174
Cohen MR, Anderson RW, Attilio RM, Green L, Muller RJ, Pruemer JM.
Preventing medication errors in cancer chemotherapy.
Am J Health Syst Pharm 1996 Apr 1;53:(7):737-46
HSL636
Caudill TS, Johnson MS, Rich EC, McKinney WP.
Physicians, pharmaceutical sales representatives, and the cost of prescribing.
Arch Fam Med 1996 Apr;5:(4):201-
HSL6659
Lexchin J, Vitry A.
Re: the promotion of Smecta (smectite)
1996 Apr;
HSL6660
This month . . . regulation of prescription drug promotion in Australia
MaLAM Australian News 1996 Apr-May;4:(4-5):1-8
HSL8347
Leifer C, McCann P.
Medicaid rebates: taming the 800-pound gorilla
Pharmaceutical Executive 1996 Apr;16:76-78, 80
HSL9160
Carlson AM, Morris LS.
Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm.
J Am Pharm Assoc (Wash) 1996 Apr;NS36:(4):263-9
HSL642
Alliot LS.
Criticism of Servier re perindopril.
Lancet 1996 Mar 23;347:(9004):832
HSL593
Soltan HC.
Violence sells.
CMAJ 1996 Mar 15;154:(6):756,
HSL635
Cho MK, Bero LA.
The quality of drug studies published in symposium proceedings.
Ann Intern Med 1996 Mar 1;124:(5):485-9
HSL623
Hemminki E, Herxheimer A.
Should drug information be an integral part of health care?
J R Coll Physicians Lond 1996 Mar-Apr;30:(2):104-6
HSL6654
This month . . . the results of MaLAM’s questionnaire to our subscribers
MaLAM Australian News 1996 Mar;4:(3):1-5
HSL6655
Clothier R.
MaLAM and pharmaceutical promotion
The Network’s Newsletter 1996 Mar;5:(1):16
HSL6656
Lexchin J, Vitry A.
Re: the promotion of Lincocin (lincomycin) and Dalacin C (clindamycin)
1996 Mar;
HSL8916
Glaser M.
Chains far outrun independents in advertising OTCs, Rxs
Drug Topics 1996 Mar;140:14s, 16s
HSL8918
Helwick C.
Are Rx-to-OTC switches fending off generic attacks?
Drug Topics 1996 Mar;140:30s, 32s
HSL8919
Breu J.
Sustained-release formulations: way out of patent expirations?
Drug Topics 1996 Mar;140:25s
HSL20386
Robertson N, Baker R, Hearnshaw H
Changing the clinical behaviour of doctors: a psychological framework
Qual Health Care. 1996 Mar;5:(1):51–54
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1055354/
HSL16728
Wolfe S, Zieve A
Don't Weaken the FDA Laws
The Washington Post 1996 Feb 28
HSL599
Rosenberg SA.
Secrecy in medical research.
N Engl J Med 1996 Feb 8;334:(6):392-4
HSL6630
Blumenthal D, Causino N, Campbell E, Louis KS.
Relationships between academic institutions and industry in the life sciences--an industry survey.
N Engl J Med 1996 Feb 8;334:(6):368-73
http://content.nejm.org/cgi/content/abstract/334/6/368
HSL9157
Reilly MJ.
Financial responsibility for adverse reactions
American Journal of Health System Pharmacy 1996 Feb 1;53:250
HSL603
Peppin JF.
Pharmaceutical sales representatives and physicians: ethical considerations of a relationship.
J Med Philos 1996 Feb;21:(1):83-99
HSL6632
Boerkamp EJ, Haaijer-Ruskamp FM, Reuyl JC, Versluis A.
The use of drug information sources by physicians: development of a data-generating methodology.
Soc Sci Med 1996 Feb;42:(3):379-88
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-3VWPKN3-29&_coverDate=02%2F29%2F1996&_alid=501643267&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1d21858b13b71b2a228e33ad94f0c0f6
HSL6650
Manitoba becomes second province to partner with PMAC knowledge campaign
PMAC News 1996 Feb;1-2
HSL6651
Sanofi Winthrop claims that Plaquenil “can help prevent the long-term damage of RA” and has a “low incidence of side effects”
MaLAM Australian News 1996 Feb;4:(2):1
HSL6652
Lexchin J, Vitry A.
Re: the promotion of Arcalion (sulbutiamine) and Duxaril (almitrine/raubasine)
1996 Feb;
HSL6653
Potts R, Vitry A.
Re: the promotion of Plaquenil (hydroxychloroquine)
1996 Feb;
HSL9149
Basara LR.
Weighing direct-to-consumer ads
Pharmaceutical Executive 1996 Feb;16:68-70
HSL627
Frankel DH.
Servier criticised in perindopril campaign
Lancet 1996 Jan 20;347:183
HSL3694
Michols D.
The distinction between advertising and other activities.
1996 Jan 12
http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/advsactv_e.pdf
HSL9183
Armstrong EP, Langley PC.
Disease management programs.
Am J Health Syst Pharm 1996 Jan 1;53:(1):53-8
HSL640
Anastasio GD, Little JM Jr.
Pharmaceutical marketing: implications for medical residency training.
Pharmacotherapy 1996 Jan-Feb;16:(1):103-7
HSL2337
Spingarn RW, Berlin JA, Strom BL.
When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?
Acad Med 1996 Jan;71:(1):86-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8540971&query_hl=61
HSL6646
The revised IFPMA code
MaLAM International News 1996 Jan;14:(1):1-2
HSL6648
Lexchin J.
Re: the promotion of Ponstan (mefenamic acid)
1996 Jan;
HSL6649
Vitry A.
Re: the promotion of Coversyl (perindopril)
MaLAM Australian News 1996 Jan;
HSL9140
Keane J.
Thrifty Payless: coming together by staying apart
Wholesale Drugs Magazine 1996 Jan;48:90, 92, 94
HSL9143
Wechsler J.
Washington report: drug wars: battles over generics and prices
Pharmaceutical Technology 1996 Jan;20:16, 18, 20, 22, 26, 28, 30, 32
HSL5405
Edwards SS, Vinicky JK, Orlowski JP.
Conflicts of interest, conflicting interests, and interesting conflicts, part 2.
J Clin Ethics 1996 Spr 01;7:(1):69-76
HSL5406
Orlowski JP, Vinicky JK, Edwards SS.
Conflicts of interest, conflicting interests, and interesting conflicts, Part 3.
J Clin Ethics 1996 Sum 01;7:(2):184-6
HSL586
Vitry A.
Pharmaceutical promotion: drug advertising affects your prescribing
Australian Prescriber 1996;19:103
HSL587
Van DER, S , Whyte SR, Hardon A.
The anthropology of pharmaceuticals: a bibliographical approach
Annual Review of Anthropology 1996;25:155-178
HSL588
Tritsmans L, Briscoe P, Lemmens P, Bussche GV.
Pharmaceutical company trials and the integrity of medical research.
Lancet 1996;
HSL591
Sullivan P.
CMA calls for controls on prescription-drug advertising aimed at patients
Can Med Assoc J 1996;154:1889-1990
HSL594
Shear NH, Black F, Lexchin J.
Examining the physician-detailer interaction
Can J Clin Pharmacol 1996;3:(4):175-179
HSL598
Roth MS.
Patterns in direct-to-consumer prescription drug print advertising and their public policy implications.
Journal of Public Policy & Marketing 1996;15:(1):63-75
HSL600
Rogers A.
Drug companies can broadcast across Europe
Lancet 1996;347:534
HSL604
Neumann PJ, Zinner DE, Paltiel AD.
The FDA and regulation of cost-effectiveness claims.
Health Aff (Millwood) 1996 Fal;15:(3):54-71
HSL606
McLaren S.
Cause and effect: prescription drug advertising goes under the microscope
Can Pharm JCan Pharm JCan Pharm J 1996;129:(5):26-30
HSL609
Lexchin J.
Direct to consumer advertising of prescription drugs: the next steps
Can J Clin Pharmacol 1996;3:(2):65
HSL610
Lewis S.
Selling guidelines door to door.
CMAJ 1996;154:756
http://www.cma.ca/cmaj/vol-154/0755e.htm
HSL614
Kopp SW.
Direct-to-consumer advertising and consumer prescription prices
Drug Information Journal 1996;30:59-65
HSL615
Kondro W.
Canada’s pharmacists can sell prescribing data
Lancet 1996;347:1401
HSL616
Kondro W.
Canadian doctors’ prescribing habits for sale
Lancet 1996;347:963
HSL618
Joseph P.
Consumer product information affects us all: iv. medical practitioner view
Australian Prescriber 1996;19:33-34
HSL619
Jewesson P, Herar S.
Activities of pharmaceutical industry representatives at a major teaching hospital.
Can J Hosp Pharm 1996;49:256-260
HSL624
Gutkin C, Handfield-jones R.
Guidelines for CME need revamping
Can Fam Physician 1996;42:1296-1297
HSL625
Greenwald M.
Marketing physician prescribing data
Ontario Medical Review 1996;63:(10):18
HSL626
Gilbert D, Chetley A.
New trends in drug promotion
Consumer Policy Review 1996;63:(5):162-167
HSL629
Fogg S.
Consumer product information affects us all: ii. consumer view
Australian Prescriber 1996;19:32
HSL630
Fisher S.
Hanky-panky in the pharmaceutical industry
International Journal of Psychopathology, Psychopharmacology and Psychotherapy 1996;1:(1):
HSL631
Dowden JS.
Consumer product information affects us all
Australian Prescriber 1996;19:30-1
HSL634
Clear PR.
Consumer product information affects us all: i. industry view
Australian Prescriber 1996;19:31-2
http://www.australianprescriber.com/magazine/19/2/30/4/
HSL641
Amonkar MM, Lively BT.
Pharmacists' attitudes toward product-specific television advertising of prescription drugs
J Pharm Mark Manage 1996;11:(2):3-20
Page 174 of 206 pages ‹ First < 172 173 174 175 176 > Last ›
